Collplant News

CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business

Yahoo FinanceApr 23 06:06 ET

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript

Yahoo FinanceApr 8 09:06 ET

CollPlant Biotechnologies Ltd (CLGN) Q4 2023 Earnings Call Transcript Highlights: A Year of ...

Yahoo FinanceApr 5 17:45 ET

Buy Rating Affirmed for Collplant Holdings on Strong Financials and Promising Product Pipeline Advancements

TipRanksApr 5 06:25 ET

Earnings Call Summary | Collplant(CLGN.US) Q4 2023 Earnings Conference

The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript:Financial Performance:CollPlant reported Q4 2023 revenues of $299,000, an increase from $58,000

moomoo AIApr 4 13:29 ET · Conference Call

CollPlant Biotechnologies' Strong Financial and R&D Progress

TipRanksApr 4 07:57 ET

CollPlant Biotechnologies Q4 Adj EPS $(0.35) Misses $(0.07) Estimate, Sales $299.00K Miss $8.56M Estimate

CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly Adj losses of $(0.35) per share which missed the analyst consensus estimate of $(0.07) by 400 percent. This is unchanged from the same period

BenzingaApr 4 07:22 ET

Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN

Collplant Biotechnologies FY23 Loss/Shr 62c >CLGN

Dow JonesApr 4 07:05 ET

Express News | CollPlant Biotechnologies Reports 2023 GAAP Revenues Of $11M, Up By $10.7M From Last Year

Moomoo 24/7Apr 4 07:04 ET

Collplant Biotechnologies Ends 2023 With $26.7M in Cash and Cash Equivalents >CLGN

Collplant Biotechnologies Ends 2023 With $26.7M in Cash and Cash Equivalents >CLGN

Dow JonesApr 4 07:04 ET

Earnings Scheduled For April 4, 2024

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. • Trinity Biotech (NASDAQ:TRIB) is projected to r

BenzingaApr 4 05:18 ET

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...

PR NewswireMar 26 08:00 ET

CollPlant Progresses in Regenerative Medicine, Highlights Key Developments

InvestingFeb 15 08:24 ET

CollPlant Issues Letter to Shareholders

PRNewswireFeb 15 08:00 ET

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

REHOVOT, Israel, Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no

PR NewswireJan 8 07:18 ET

CollPlant Biotechnologies Begins Preclinical Trial With Commercial-Size, Regenerative Breast Implants

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...

PR NewswireJan 2 07:00 ET

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript

Yahoo FinanceDec 1, 2023 09:58 ET

Earnings Call: CollPlant Biotechnologies Q3 2023 Results Highlight Resilience Amid Conflict, Focus on Regenerative Medicine

InvestingDec 1, 2023 09:22 ET

Analysts' Top Healthcare Picks: Collplant Holdings (CLGN), UnitedHealth (UNH)

TipRanksNov 30, 2023 06:30 ET

HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $11 price target.

BenzingaNov 30, 2023 06:26 ET